AI assistant
PAINCHEK LTD — Capital/Financing Update 2021
Jan 7, 2021
65534_rns_2021-01-07_155260a6-02f9-4a3a-acb2-65d069577f9f.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
ASX ANNOUNCEMENT 8 January 2021
==> picture [182 x 42] intentionally omitted <==
PainChek Receives R&D Tax Incentive
PainChek® Ltd (ASX: PCK) (“PainChek®” or “the Company”), developer of the world’s first smart phone-based pain assessment and monitoring application, is pleased to announce it has received $979,621 for the FY20 R&D Tax Incentive.
This significant receipt adds to the Company’s well-funded cash position which currently stands at approx. A$13 million.
This release has been authorized for release by CEO Philip Daffas.
For more information:
Ian Hobson Philip Daffas Company Secretary, PainChek CEO, PainChek [email protected] [email protected] +61 8 9388 8290 0406 537 235
About PainChek®
PainChek® Ltd is an Australian based company that develops pain assessment technologies.
PainChek® is a smart phone based medical device using artificial intelligence to assess and score pain levels in real time and update medical records in the cloud. PainChek® records a short video of the person’s face and analyses the images that indicate pain and records them.
Next, the caregiver uses PainChek® to record their observations of other pain related behaviours that complete the assessment. Finally, PainChek® calculates an overall pain score and stores the result allowing the caregiver to monitor the effect of medication and treatment over time.
PainChek® is being rolled out globally in two phases: first, PainChek® for adults who are unable to effectively verbalise their pain such as people with dementia, and second, PainChek® for Children who have not yet learnt to speak.
The PainChek® Shared Care Program is a PainChek® licensing model which enables a professional carer to share their resident or patient data securely with other healthcare professionals or designated homebased family carers for ongoing pain assessments or clinical data review.
To find out more, visit www.painchek.com
ABN 21 146 035 127 P: +61 8 9388 8290 401, 35 Lime Street, E: [email protected] Sydney, NSW, 2000 W: painchek.com